文献速递血栓与止血

瑞舒伐他汀治疗降低静脉血栓栓塞后血浆促凝磷脂活性:一项随机对照试验

Rosuvastatin treatment decreases plasma procoagulant phospholipid activity after a VTE: A randomized controlled trial.
PubMed 文献 · J Thromb Haemost · 2022-01-08

在既往静脉血栓栓塞(VTE)且已停抗凝的患者中,随机接受瑞舒伐他汀20 mg/日或不治疗28天;瑞舒伐他汀使血浆促凝磷脂(PPL)活性总体降低22%(95%CI -38.2至-5.8),肺栓塞史者降低37%(95%CI -62.9至-11.2),该效应不能由总胆固醇或细胞外囊泡水平变化解释。

要点

  • 瑞舒伐他汀20 mg/日治疗28天使血浆PPL活性总体降低22%。
  • 有肺栓塞史者PPL活性降低37%,效应大于总体人群。
  • PPL活性降低不能由总胆固醇或总/血小板来源细胞外囊泡变化解释。

核心结论

  • 瑞舒伐他汀治疗使血浆PPL活性大幅降低,提示PPL依赖的凝血活化减弱可能有助于他汀治疗后VTE风险降低。

研究设计与样本

  • Statins Reduce Thrombophilia(NCT01613794)随机对照试验,纳入≥18岁、有VTE史且允许停抗凝治疗的患者,随机接受瑞舒伐他汀20 mg/日或不治疗28天。
  • 基线与研究结束时采集血浆,245名参与者的样本用Xa因子依赖性凝血试验测PPL活性,用流式细胞术测细胞外囊泡水平。

主要发现

  • 瑞舒伐他汀治疗使PPL活性总体降低22%(95%CI -38.2至-5.8)。
  • 有肺栓塞史的参与者PPL活性降低37%(95%CI -62.9至-11.2)。
  • 瑞舒伐他汀对血浆PPL活性的效应不能由总胆固醇变化或总/血小板来源细胞外囊泡水平变化解释。

关键数值与推荐

  • 瑞舒伐他汀剂量为20 mg/日,疗程28天。
  • PPL活性用Xa因子依赖性凝血试验测定,细胞外囊泡水平用流式细胞术测定。
  • PPL活性总体降低22%(95%CI -38.2至-5.8),肺栓塞史者降低37%(95%CI -62.9至-11.2)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Venous thromboembolism (VTE) is a frequent cardiovascular disease with severe complications, including recurrence and death. There is a great need for alternative prophylactic treatment options as anticoagulation is accompanied by increased bleeding risk. Statins are reported to reduce the risk of incident and recurrent VTE, but the mechanisms are elusive. Procoagulant phospholipids (PPL), and phosphatidylserine in particular, are crucial for efficient coagulation activation, but no studies have investigated the effect of statin treatment on plasma PPL activity. OBJECTIVES: To investigate the impact of rosuvastatin treatment on plasma PPL activity and levels of extracellular vesicles (EVs). PATIENTS/METHODS: Patients with a history of VTE (≥18 years) allowed to stop anticoagulant treatment were randomized to either 20 mg/day of rosuvastatin treatment or no treatment for 28 days in the Statins Reduce Thrombophilia (NCT01613794) trial. Plasma samples were collected at baseline and study end. PPL activity was measured in samples from 245 participants using a factor Xa-dependent clotting assay and EV levels by flow cytometry. RESULTS: Rosuvastatin treatment yielded an overall 22% (95% confidence interval [CI] -38.2 to -5.8) reduction in PPL activity, and 37% (95% CI -62.9 to -11.2) reduction in PPL activity in participants with a history of pulmonary embolism. The effect of rosuvastatin on plasma PPL activity was not explained by changes in total cholesterol nor change in levels of total- or platelet-derived EVs. CONCLUSIONS: Rosuvastatin treatment caused a substantial decrease in plasma PPL activity, suggesting that a PPL-dependent attenuation of coagulation activation may contribute to a reduced VTE risk following statin treatment.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Ramberg C, Hindberg K, Biedermann JS, et al. Rosuvastatin treatment decreases plasma procoagulant phospholipid activity after a VTE: A randomized controlled trial. J Thromb Haemost. 2022. PMID: 34953155. doi:10.1111/jth.15626

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。